Fadi H Mourad
Overview
Explore the profile of Fadi H Mourad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nammour T, Jamal L, Hosni M, Tamim H, Kerbage A, Hashash J, et al.
J Clin Gastroenterol
. 2022 Aug;
57(7):700-706.
PMID: 35921332
Goals And Background: We aimed to develop a novel 1-year mortality risk-scoring system that includes use of antithrombotic (AT) drugs and to validate it against other scoring systems in patients...
12.
El Hage Chehade N, Ghoneim S, Shah S, Chahine A, Mourad F, Francis F, et al.
Inflamm Bowel Dis
. 2022 Jun;
29(5):808-817.
PMID: 35766805
Background: Fecal microbiota transplantation (FMT) has been investigated as a treatment option for patients with inflammatory bowel disease with controversial results.We sought to perform a systematic review and meta-analysis to...
13.
Mourad F, Hashash J
Lancet Gastroenterol Hepatol
. 2021 Nov;
7(1):13.
PMID: 34774193
No abstract available.
14.
Aoun R, Jabak S, Mourad F, Francis F, Regueiro M, Hashash J
J Clin Gastroenterol
. 2021 Jul;
55(9):740-746.
PMID: 34294654
The therapeutic armamentarium for patients with inflammatory bowel disease has been expanding. Current guidelines make recommendations about whether patients who are biologic naive should be receiving biologic monotherapy or combination...
15.
Hosni M, Rahal M, Tamim H, Daniel F, Al Hashash J, Sharara A, et al.
Eur J Gastroenterol Hepatol
. 2021 Apr;
33(1S Suppl 1):e490-e498.
PMID: 33867445
Background/aim: We determined the effect of antiplatelet and anticoagulant agents on rebleeding and mortality in patients with gastrointestinal bleeding. Methods: This was a prospective study of patients admitted with gastrointestinal...
16.
Hashash J, Mourad F
Curr Opin Gastroenterol
. 2021 Mar;
37(4):351-356.
PMID: 33731644
Purpose Of Review: Since there is a lack of head-to-head randomized controlled trials, little direction is provided from guidelines on the positioning of biologics for the treatment of Crohn's disease...
17.
Kariyawasam V, Mourad F, Mitrev N, Paramsothy S, Selinger C, Katelaris P, et al.
Eur J Gastroenterol Hepatol
. 2021 Mar;
33(12):1524-1532.
PMID: 33731581
Background: Thiopurines effectively maintain remission in ulcerative colitis patients. Whether early initiation of thiopurines after ulcerative colitis diagnosis decreases proximal disease progression and colectomy rates is not known. Methods: We...
18.
19.
Chan W, Kariyawasam V, Kim S, Pudipeddi A, Paramsothy S, Shim H, et al.
Eur J Gastroenterol Hepatol
. 2020 May;
32(8):976-983.
PMID: 32453008
Background And Aims: Comorbidities, polypharmacy, malignancies, and infections complicate management of elderly patients with inflammatory bowel diseases (IBD). This study assessed gastroenterologists' preference in the prescription of medications or surgery...
20.
Mourad F, Hashash J, Kariyawasam V, Leong R
J Crohns Colitis
. 2020 Feb;
14(8):1162-1171.
PMID: 32103246
Despite multiple studies, the role of cytomegalovirus [CMV] infection in exacerbating the severity of inflammation in ulcerative colitis [UC], and its response to treatment, remain debatable. Additionally, the optimal diagnostic...